This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2006 by Johns Hopkins University.
Recruitment status was:  Not yet recruiting
Janssen-Cilag Ltd.
Information provided by:
Johns Hopkins University Identifier:
First received: August 21, 2006
Last updated: NA
Last verified: August 2006
History: No changes posted
This study seeks to test the Efficacy in terms of rates of disease response in metastatic nasopharyngeal carcinoma of the standard dose of velcade 1.3 mg/m2 given at the day 1,4,8,and 11 every 21 days schedule. The study uses a Simons 2 stage design and will enroll between 15-25 patients. Secondary endpoints studied include Pharmacokinetics, toxicities, EBV viral load and molecular characterization of EBV in plasma.

Condition Intervention Phase
Nasopharyngeal Carcinoma Drug: Velcade Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma

Resource links provided by NLM:

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • Efficacy based on response of measurable disease

Secondary Outcome Measures:
  • EBV viral load
  • toxicities
  • Molecular characterization of EBV in plasma

Estimated Enrollment: 25

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biopsy proven nasopharyngeal carcinoma – WHO type 3 (recurrence or metastases)
  • metastatic disease or locally recurrent disease not amendable curative therapy
  • Patients must have measurable disease
  • least one (not more than a total of three prior lines of chemotherapy for metastatic or recurrent disease). This must include at least 1 prior line of platinum-containing chemotherapy.
  • An ECOG performance status of 0–2
  • Absolute neutrophil count (ANC) ≥1500/mm3
  • Hemoglobin  8g/dl (blood transfusion is allowed to correct hemoglobin level).
  • PLT ≥ 75,000/mm 3
  • Total bilirubin ≤ 2 x upper normal limit (UNL)
  • Serum ALT ≤ 5 x UNL
  • Serum creatinine ≤ 2 mg/dL
  • Serum albumin ≥ 2.5 g/dL
  • No known history of brain or leptomeningeal metastasis.
  • ≥ 18 years of age.
  • Estimated life expectancy ≥ 24 weeks.
  • For sexually active women of childbearing potential, negative pregnancy test within 21 days of enrolling on trial.
  • must be able to give informed written consent

Exclusion Criteria:

  • Patients who have not had at least 1 or more than 3 previous lines of treatment for metastatic or recurrent NPC
  • Prior BORTEZOMIB therapy
  • Immunotherapy ≤ 4 weeks have elapsed prior to study entry
  • Biologic therapy ≤ 4 weeks have elapsed prior to study entry
  • Radiation therapy ≤ 4 weeks have elapsed prior to study entry
  • Major surgery, or significant traumatic injury ≤3 weeks prior to study entry
  • Other concurrent chemotherapy, immunotherapy, radiotherapy, or any other therapy or supportive care considered investigational
  • Evidence of CNS involvement
  • Presence of > grade 1 sensory peripheral neuropathy of any etiology OR grade 1 with neuropathic pain of any etiology.
  • Patients with significant local symptoms from metastases which is amenable to radiotherapy
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to BORTEZOMIB.
  • History of other malignancy ≤ 3 years prior to study entry, except for adequately treated basal cell, squamous cell skin cancer or cervical intraepithelial neoplasia.
  • Uncontrolled intercurrent illness
  • Patients who are pregnant or breast feeding (Sexually active men and women of childbearing potential must use contraception during course of therapy and within 3 months of completion of trial) Participation in another clinical trial involving therapeutic intervention within 4 weeks of enrollment.
  • Known history of HIV
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00367718

Contact: Carol Loo (65) 6772-4619
Contact: Yoke Fong Lai (65) 68802215

Chinese University of Hong Kong Not yet recruiting
Hong Kong, China
Contact: Brigette Ma, M.D.   
Principal Investigator: Brigette Ma, M.D.         
Johns Hopkin Singapore International Medical Center
Singapore, Singapore
National University Hospital of Singapore Recruiting
Singapore, Singapore
Contact: Boon Cher Goh, M.D.   
Principal Investigator: Boon Cher, M.D.         
Sponsors and Collaborators
Johns Hopkins University
Janssen-Cilag Ltd.
Study Chair: Wen-son Hsieh, M.D. Johns Hopkins Singapore-International Medical Center
Study Chair: Brigette Ma, M.D. Chinese University of Hong Kong
  More Information Identifier: NCT00367718     History of Changes
Other Study ID Numbers: CTRG-NP04/23/06
Study First Received: August 21, 2006
Last Updated: August 21, 2006

Additional relevant MeSH terms:
Nasopharyngeal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Nasopharyngeal Diseases
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Antineoplastic Agents processed this record on August 17, 2017